All In MedTech

Device Trial Radar · NCT05480904

Characterizing Sleep Among Long-term Survivors of Childhood Cancer

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

199

Planned (sponsor's estimate)

Start

Apr 17, 2023

Primary completion

Apr 29, 2026

Study completion Jan 2027

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 29, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The patients are being asked to take part in this clinical trial because they received cancer treatment as a child at St. Jude. The study comprehensively examines sleep among three distinct diagnostic groups of survivors in the SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors. Primary Objective The primary aim of this protocol is to estimate the prevalence of various sleep disorders among long-term survivors of childhood ALL, CNS tumors, and non- CNS solid tumors. Exploratory Objective The exploratory objective of the study is to explore associations between the prevalence of sleep disorders and clinical outcomes collected in SJLIFE.

Conditions

  • ALL, Adult
  • CNS Tumor
  • Solid Tumor

Interventions

  • Neurocognitive (Thinking) TestingOther

    Intelligence: WASI-II 20 min; Sustained Attention: Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min.

  • CNS Vital Signs (Thinking) TestingDiagnostic test

    Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins

  • Health Questionnaires, Sleep Surveys & Sleep DiaryOther

    The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.

  • Echocardiography/EKGDiagnostic test

    All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography

  • Pulmonary FunctionDiagnostic test

    PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).

  • Remote PolysomnographyDevice

    The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.

  • Physical FunctionDiagnostic test

    This is a test of how your heart and lungs respond to exercise.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Insomnia Severity Index (ISI)Time frame: Baseline
  2. CSALTS Sleep SurveyTime frame: Baseline
  3. Morningness-Eveningness Questionnaire (MEQ)Time frame: Baseline

4 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.